Matthew Jenusaitis Buys 9,620 Shares of enVVeno Medical Corporation (NASDAQ:NVNO) Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Matthew Jenusaitis acquired 9,620 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The shares were acquired at an average price of $2.53 per share, with a total value of $24,338.60. Following the acquisition, the director now owns 16,545 shares in the company, valued at $41,858.85. This trade represents a 138.92 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

enVVeno Medical Trading Down 1.6 %

Shares of NVNO stock opened at $2.49 on Monday. The stock has a market capitalization of $43.66 million, a price-to-earnings ratio of -1.93 and a beta of 1.22. enVVeno Medical Corporation has a twelve month low of $2.45 and a twelve month high of $6.97. The stock has a fifty day simple moving average of $3.22 and a two-hundred day simple moving average of $4.36.

enVVeno Medical (NASDAQ:NVNO) last posted its earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). Research analysts predict that enVVeno Medical Corporation will post -1.3 EPS for the current fiscal year.

Hedge Funds Weigh In On enVVeno Medical

Several institutional investors and hedge funds have recently modified their holdings of the stock. Corsair Capital Management L.P. acquired a new position in shares of enVVeno Medical during the third quarter valued at approximately $390,000. Maven Securities LTD acquired a new position in shares of enVVeno Medical during the 3rd quarter worth approximately $295,000. Geode Capital Management LLC grew its position in shares of enVVeno Medical by 7.8% in the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock valued at $506,000 after purchasing an additional 10,902 shares in the last quarter. Hohimer Wealth Management LLC acquired a new stake in enVVeno Medical during the third quarter worth about $286,000. Finally, Westside Investment Management Inc. raised its position in shares of enVVeno Medical by 128.0% during the 3rd quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock valued at $297,000 after buying an additional 49,613 shares during the period. Institutional investors and hedge funds own 34.71% of the company’s stock.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).